Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
52 results about "Interstitial fibrosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Interstitial pulmonary fibrosis is a form of interstitial lung disease characterized by the thickening and scarring of lung tissue. Frequently diagnosed as an idiopathic condition, meaning there is no known or obvious cause for its development, interstitial pulmonary fibrosis is a noninfectious,...
Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
InactiveUS20080175887A1Promote absorptionOrganic active ingredientsPowdered material dispensingDiseaseObstructive Pulmonary Diseases
Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).
Owner:LUTONIX INC
Treatment of asthma and chronic obstructive pulmonary disease with Anti-proliferate and Anti-inflammatory drugs
ActiveUS20130261603A1Promote absorptionRespiratorsPowder deliveryDiseaseObstructive Pulmonary Diseases
Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.
Owner:LUTONIX INC
Gene expression profiles associated with chronic allograft nephropathy
ActiveUS20120178642A1Nucleotide librariesMicrobiological testing/measurementChronic allograft nephropathyTubular atrophy
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and / or interstitial fibrosis and tubular atrophy CAN / IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and / or subtyping of CAN / IFTA.
Owner:THE SCRIPPS RES INST
Compound of sphaeria sinensis and panax notoginseng extract and the application thereof in the preventing and treating of pulmonary fibrosis
The invention discloses a cordycepin extract and notoginseng extract and application in prevention and cure pulmonary fibrosis medicine preparation, which is characterized by the following: extracting and condensing from China clothing hairs pore zymocyte powder with water and alcohol; getting cordycepin extract; setting Cordyceps sinensis adenosine, cordycepic acid, and Cordyceps sinensis polysaccharide more than raw bacteria powder about 3-8 double; extracting cordycepin extract from cordycepin crude drug with alcohol; separating large aperture absorption resin; purifying; getting the cordycepin extract; setting the content of cordycepin saponin more than raw cordycepin crude drug for 7-10 double; allocating the cordycepin and cordycepin saponin with mass percent at 90-10% and 10-90%; preparing medicinal compound. This invention possesses very big utility value in clinic.
Owner:苏州中药研究所有限公司 +1
Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
InactiveUS20120046181A1Solid foundationPeptide librariesLibrary screeningRenal transplantBiomarker (petroleum)
The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and / or monitoring of treatment regimens.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
The present invention is directed to a method of treating a subject for a pulmonary disease by administering a therapeutically effective amount of a compound of the formula:wherein R1, R2 or R3 are each independently a C1 to C6 alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, atrial septal defects, and pulmonary diseases associated with other conditions. If this same compound is modified so that R1, R2 or R3 each independently is a C1 to C6 alkyl and the compound is not a carbonic acid inhibitor, it can be administered to a subject to block hypoxic pulmonary vasoconstriction and / or prevent high altitude pulmonary edema. Additional aspects of the present invention include an inhalable composition comprising the compound of the above formula without modification and an inhalable carrier, as well as the above modified compound.
Owner:UNIV OF WASHINGTON
Novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome and preparation method
PendingCN110038032AInhibit interstitial fibrosisProtect kidney functionMetabolism disorderTransferasesTreatment effectMagnetic bead
The invention belongs to the technical field of a biological preparation, and discloses a novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome and a preparation method. The novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome has main component of cup-shaped membrane-shaped vesicles which are prepared through combination of intracellular multivesicular bodies with cell membranes, are secreted outside cells and are about 100nm in size. The preparation method of the novel biological preparation for resisting renal fibrosis, of human umbilical cord MSC exosome comprises an ultracentrifugation method, a chemical reagent precipitation method, an ultrafiltration and centrifugation method and a magnetic bead immunization method. When the MSC cell exosome is extracted and used for treatment of an animal model suffering from diabetic nephropathy, the inventor finds that MSC-Ex has the treatment effects of restraining YAP activity, allevaiting renal interstitial fibrosis and delaying diabetic nephropathy.
Owner:JIANGSU UNIV
Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof
InactiveCN102370738AImprove antioxidant capacityInhibit overexpressionUrinary disorderPlant ingredientsRenal glomerulusAngelica Sinensis Root
The invention belongs to the field of Chinese medicines, and relates to a Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis and a preparation method thereof. On the basis of the theory of 'body resistance weakened while pathogenic factors prevailing, insufficiency of Qi and blood, and blood stasis and collaterals obstruction' in traditional Chinese medical science, the Chinese medicinal compound preparation is prepared from Chinese medicines such as Danshen root, angelica sinensis, peach kernel, twotooth achyranthes root and processed rhubarb. Through animal experiment and clinical trial, the Chinese medicinal compound preparation can improve renal haemodynamics, adjust lipid metabolic disturbance, enhance oxidation resistance, and inhibit over expression of cell factors so as to improve glomerulosclerosis and interstitial fibrosis degree, protect residual renal structures and functions, and delay the process of early-stage and medium-stage chronic renal failure deterioration. The Chinese medicinal compound preparation is particularly suitable for treating patients who suffer from chronic kidney disease (CKD2-4) and renal fibrosis which comprise renal insufficiency, proteinuria, atrophy of kidney and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Application of fucoidan polysaccharide sulfate in preparing drug for preventing and/or treating diabetic cardiomyopathy
ActiveCN103230411ALittle side effectsIncreased systolic functionOrganic active ingredientsMetabolism disorderCardiac fibrosisAntioxidative enzyme
The invention discloses a drug novel use of fucoidan polysaccharide sulfate. The use is the application of the fucoidan polysaccharide sulfate in preparing the following products: (1), a product for preventing and / or treating diabetic cardiomyopathy; (2), a product for inhibiting diabetic myocardial oxidative stress; and (3), a product for inhibiting expression and activation of PKC (Protein Kinase C) beta in diabetic cardiomyopathy; and (4), a product for relieving cardiac interstitial fibrosis of a diabetic. The fucoidan polysaccharide sulfate is preferably LMWF (Fucoidan Polysaccharide Sulfate) with weight-average molecular weight of 3-30KD. According to the pharmacodynamic experiment, the LMWF can be used for generating beneficial interference to the development of pathogenetic condition of the diabetic cardiomyopathy by strengthening the myocardial systolic function and relieving cardiac fibrosis. More importantly, the LMWF can be used for effectively inhibiting oxidative stress by regulating the activity of antioxidase, and can be used for inhibiting the expression of protein kinase C beta (PKCbeta) subtype. The LMWF is from the natural existing kelp, so that the availability and safety of the kelp are beneficial to using the fucoidan polysaccharide sulfate as a potential clinical treatment drug and preventing the diabetic cardiomyopathy.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Chinese medicinal composition for treating pulmonary interstitial fibrosis
InactiveCN101543574AQuality improvementDefinite curative effectAnthropod material medical ingredientsRespiratory disorderDiseaseRHODIOLA ROSEA ROOT
The invention relates to a Chinese medicinal composition for treating pulmonary interstitial fibrosis, which comprises the following Chinese medicinal components by weight portion: 1 portion of unibract fritillary bulb, 0.1 to 1.0 portion of Paecilomyces bepiali chen, 1.5 to 4 portions of pseudo-ginseng, 1 to 3 portions of Rhodiola rosea L., 1 to 5 portions of Breviscapinun, 1 to 5 portions of red sage root, 1 to 3 portions of ginkgo leaf, 0.1 to 0.6 portion of sanguisuga, 0.1 to 0.6 portion of earthworm and 1 to 5 portions of Common Anemarrhena Rhizome; and the Chinese medicinal components are raw powder of the Chinese medicinal materials or Chinese medicinal extracts equal to crude drug dosages of the Chinese medicinal materials. The Chinese medicinal composition can be used for treating diseases such as pulmonary interstitial fibrosis and the like.
Owner:BEIJING NORMAL UNIVERSITY
Macrolide derivatives
InactiveCN101454334AInhibition of antimicrobial activityAntibacterial agentsOrganic active ingredientsRESPIRATORY DISTRESS SYNDROME ADULTLymphatic Spread
Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).
Owner:TAISHO PHARMACEUTICAL CO LTD
Application of nuclear receptor ROR alpha in preparation of anti-heart failure drugs
InactiveCN108939048AImproved heart failurePromote hypertrophyPeptide/protein ingredientsCardiovascular disorderCardiac muscleCardiac failures
The invention provides application of a nuclear receptor ROR alpha in the preparation of anti-heart failure drugs. The nuclear receptor ROR alpha is a nuclear receptor ROR alpha 1 subtype; the gene sequence of the nuclear receptor ROR alpha 1 is as shown in SEQ ID NO. 1; and the amino acid sequence of the nuclear receptor ROR alpha 1 is as shown in SEQ ID NO. 2. Experiments find that the expression of the nuclear receptor ROR alpha provided by the invention in hypertrophic and failing myocardial tissues is down-regulated, and the loss of ROR alpha can aggravate cardiac hypertrophy and cardiacfailure. The overexpression of myocardial-specific ROR alpha can alleviate TAC-induced myocardial interstitial fibrosis and improve the cardiac hypertrophy and cardiac failure. The nuclear receptor ROR alpha has an effect against cardiac hypertrophy and cardiac failure.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Application of CTRP3 to preparation of drugs for preventing and treating cardiac hypertrophy
InactiveCN108904782AReduce apoptosisImprove heart functionPeptide/protein ingredientsCardiovascular disorderEccentric hypertrophySystole
The invention discloses the application of CTRP3 to preparation of drugs for preventing and treating cardiac hypertrophy. A pathologic hypertrophy model of cells is established in the invention, and the pathologic hypertrophy model proves that administration of CTRP3 can lower the expression of cardiac hypertrophy marker molecules and reduce the average surface area of cardiac muscle cells. An in-vivo animal model is also established in the invention, and the in-vivo animal model proves that after administration of CTRP3, the heart-to-body ratio and the lung-to-body ratio of a mouse significantly decrease, the left ventricular systolic function of the heart of the mouse is significantly improved; interventricular septal thickness in a systolic period and left ventricular posterior wall thickness in a diastolic period are significantly reduced; the cross-sectional areas of myocardial cells significantly decrease; the myocardial cells are arranged more closely and regularly; the degreesof myocardial tissue interstitial fibrosis and pericapillary fibrosis are greatly lowered; and thus, it is indicated that CTRP3 has significant prevention effect on pathological cardiac hypertrophy, delays the occurrence of heart failures, and has good clinical application prospects.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Gene expression profiles associated with chronic allograft nephropathy
By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and / or interstitial fibrosis and tubular atrophy CAN / IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and / or subtyping of CAN / IFTA.
Owner:THE SCRIPPS RES INST
Application of oridonin in preparation of cardiac remodeling resistant medicines
ActiveCN107157980APrevent deterioration of heart functionSignificant anti-myocardial remodeling effectOrganic active ingredientsCardiovascular disorderCardiac muscleCardiac muscle cell hypertrophy
Owner:WUHAN UNIV
Method for targeting cells involved in sclerotic and/or fibrotic diseases
A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
Owner:BIORION TECH
Method to prevent transplant rejection by stable expression of heme oxygenase-1
InactiveUS20050142111A1BiocideGenetic material ingredientsTransplant arteriosclerosisTransplant rejection
The present invention relates to a method for the prevention of allograft rejection in clinical transplantation. Specifically, the method of the present invention relates to the prevention of transplant arteriosclerosis and interstitial fibrosis by stable and long-term expression of HO-1 in grafts. The present invention represents a novel therapeutic approach to prevent allograft rejection in clinical transplantation.
Owner:AGTC GENE TECH CO LTD
Methods of treating pulmonary disease using acetazolamide and structurally related derivatives
The present invention is directed to a method of treating a subject for a pulmonary disease by administering a therapeutically effective amount of a compound of the formula:wherein R1, R2 or R3 are each independently a C1 to C6 alkyl, a halogen, a sulfate, or a phosphate. The pulmonary disease in the subject can be hypoxic pulmonary vasoconstriction, pulmonary edema, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial fibrosis, high altitude residence, sleep apnea syndrome, atrial septal defects, and pulmonary diseases associated with other conditions. If this same compound is modified so that R1, R2 or R3 each independently is a C1 to C6 alkyl and the compound is not a carbonic acid inhibitor, it can be administered to a subject to block hypoxic pulmonary vasoconstriction and / or prevent high altitude pulmonary edema. Additional aspects of the present invention include an inhalable composition comprising the compound of the above formula without modification and an inhalable carrier, as well as the above modified compound.
Owner:UNIV OF WASHINGTON
Applications of Kindlin-2 protein as target point in preparing medicines for treating nephritis
ActiveCN107137710AElevated urine proteinDecrease in plasma proteinDisease diagnosisPharmaceutical non-active ingredientsMedicineNephritis
The invention relates to applications of Kindlin-2 protein as a target point in preparing medicines for treating nephritis. The research result shows that after the Kindlin-2 gene is specifically knocked out, the content of urine protein of mice is obviously increased, while the content of plasma protein is obviously reduced, meanwhile, the structure of glomeruli of the kidney is severely damaged, and the obvious glomerular sclerosis and interstitial fibrosis exist. The experimental result of the research shows that Kindlin-2 protein can be taken as a novel target point for preparing the medicines for treating nephritis.
Owner:SOUTH UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA
Application of tetrahydroberberrubine in preparation of heart protection medicine
ActiveCN113786405AImprove protectionBlock the remodeling processOrganic active ingredientsCardiovascular disorderCardiac dysfunctionPharmaceutical drug
The invention relates to an application of tetrahydroberberrubine in preparation of a heart protection medicine. Pharmacological experiments of tetrahydroberberrubine show that tetrahydroberberrubine can significantly improve cardiac dysfunction induced by pressure load, and has an obvious heart protection effect; and meanwhile, myocardial cell hypertrophy and interstitial fibrosis can be remarkably inhibited, the heart remodeling process is prevented, and the heart is prevented from entering the heart failure stage. In addition, the tetrahydroberberrubine compound is high in bioavailability, low in toxicity, stable and easy to produce, transport, store and take, and is a heart protection medicine with a wide application prospect.
Owner:HARBIN MEDICAL UNIVERSITY
Intratracheal administration of lysozyme with other therapeutic agents in the prevention and treatment of respiratory disorders
The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The method is intended for a variety of mammals, including humans ranging from premature neonates to adults.
Owner:CANTOR JEROME OWEN +1
Biomagnetic traditional Chinese medicine for treating lung disease and preparation method of biomagnetic traditional Chinese medicine
InactiveCN108245614AEasy breathingAchieve functionAntibacterial agentsNervous disorderPulmonary parenchymaRadix Astragali seu Hedysari
The invention discloses biomagnetic traditional Chinese medicine for treating a lung disease and a preparation method of the biomagnetic traditional Chinese medicine. The preparation method of the biomagnetic traditional Chinese medicine comprises the following steps: step A, selecting and washing traditional Chinese medicine raw materials of radix panacis quinquefolii, bulbus fritillariae ussuriensis, fructus trichosanthis, semen armeniacae amarae, radix astragali seu hedysari, bulbus lilii, radix ophiopogonis, radix rehmanniae preparata and liquorice root, and mixing the traditional Chinesemedicine raw materials, thus forming a traditional Chinese medicine mixture; step B, soaking the traditional Chinese medicine mixture for 0.5 to 2 hours, decocting for 10 to 20 minutes, and separatingmedicine residue and first liquid medicine; step C, adding water in the medicine residue, decocting for 15 to 25 minutes, and separating the medicine residue and second liquid medicine. The biomagnetic traditional Chinese medicine for treating the lung disease, disclosed by the invention, has a very obvious therapeutic effect; the biomagnetic traditional Chinese medicine has the effects of rapidly penetrating through a focus and removing diffusive pulmonary parenchyma and pulmonary alveolitis; a biomagnetic medicine filed (H) has the effects of penetrating, softening and activating the focuson interstitial fibrosis, and pathogenic cells and virus activating factors are cleared while benign cells are recovered.
Owner:李春伸 +1
Composition for improving kidney dysfunction, black ginseng extract and preparation method and application thereof
InactiveCN109793746AImprove kidney functionImprove renal insufficiencyOrganic active ingredientsUrinary disorderGINSENG EXTRACTDeep processing
The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.
Owner:YANBIAN UNIV
Cordyceps cicadae composite medicine for treating diabetic nephropathy and preparation method thereof
InactiveCN108245606AGood treatment effectImprove protectionAnthropod material medical ingredientsMetabolism disorderLiver and kidneyRadix Astragali seu Hedysari
The invention provides cordyceps cicadae composite medicine for treating diabetic nephropathy and a preparation method thereof and belongs to the field of traditional Chinese medicine. The cordyceps cicadae composite medicine for treating diabetic nephropathy is prepared from the following raw materials in parts by weight: 18 to 22 parts of cordyceps cicadae, 14 to 16 parts of radix rehmanniae, 14to 16 parts of common yam rhizome, 8 to 12 parts of fructus lycii, 8 to 12 parts of fructus corni, 8 to 12 parts of achyranthes root, 14 to 16 parts of fried radix astragali seu hedysari, 8 to 12 parts of radix salvia miltiorrhizae, 8 to 12 parts of poria with hostwood and 5 to 7 parts of chamomile flower. The composite medicine has scientific and rigovous compatibility and complete assistant andguide and has the effects of tonifying qi and yin, promoting blood circulation to remove blood stasis, nourishing liver and kidney and can achieve an effect of treating both symptoms and root causeson the diabetic nephropathy. Research data show that aqueous extract of the cordyceps cicadae composite medicine can effectively inhibit aldose reductase and reduce expression of TGF-beta1 protein, alpha-SMA protein and FN protein of renal tubular epithelial cells; thus, damage to the glomerulus cells is reduced, glomerular sclerosis is relieved, tubular interstitial fibrosis is inhibited, pathological change of the kidney is lightened, illness state development can be inhibited and converted, and a better treating and protecting effect on the diabetic nephropathy is achieved.
Owner:WUXI NO 2 PEOPLES HOSPITAL
Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof
InactiveCN102370738BImprove antioxidant capacityInhibit overexpressionUrinary disorderPlant ingredientsRenal glomerulusAngelica Sinensis Root
The invention belongs to the field of Chinese medicines, and relates to a Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis and a preparation method thereof. On the basis of the theory of 'body resistance weakened while pathogenic factors prevailing, insufficiency of Qi and blood, and blood stasis and collaterals obstruction' in traditional Chinese medical science, the Chinese medicinal compound preparation is prepared from Chinese medicines such as Danshen root, angelica sinensis, peach kernel, twotooth achyranthes root and processed rhubarb. Through animal experiment and clinical trial, the Chinese medicinal compound preparation can improve renal haemodynamics, adjust lipid metabolic disturbance, enhance oxidation resistance, and inhibit over expression of cell factors so as to improve glomerulosclerosis and interstitial fibrosis degree, protect residual renal structures and functions, and delay the process of early-stage and medium-stage chronic renal failure deterioration. The Chinese medicinal compound preparation is particularly suitable for treating patients who suffer from chronic kidney disease (CKD2-4) and renal fibrosis which comprise renal insufficiency, proteinuria, atrophy of kidney and the like.
Owner:SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Application of lactucopicrin in preparation of medicine for preventing and treating heart failure and pathological cardiac remodeling
ActiveCN112773789AValid choiceOral convenienceOrganic active ingredientsCardiovascular disorderPharmaceutical medicineBULK ACTIVE INGREDIENT
The invention relates to the technical field of biological medicines, in particular to application of lactucopicrin in preparation of a medicine for preventing and treating heart failure and pathological cardiac remodeling. The medicine takes the lactucopicrin as an active ingredient, which can be mixed with pharmaceutically acceptable, inert and non-toxic excipients or carrier auxiliary materials to prepare the clinical medicine convenient for oral administration or intravenous application. Specifically, the invention relates to application of the lactucopicrin in preparation of a medicine for resisting heart failure, application of the lactucopicrin in preparation of a medicine for resisting cardiac insufficiency, application of the lactucopicrin in preparation of a medicine for resisting pathological cardiac remodeling, an effect of the lactucopicrin in preparation of a medicine for resisting cardiomyocyte hypertrophy, application of the lactucopicrin in preparation of a medicine for resisting myocardial interstitial fibrosis and application of the lactucopicrin in preparation of a medicine for resisting myocardial cell death.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Application of leucanthin in the preparation of drugs for the prevention and treatment of heart failure and pathological cardiac remodeling
ActiveCN112773789BValid choiceOral convenienceOrganic active ingredientsCardiovascular disorderBULK ACTIVE INGREDIENTPharmaceutical Aids
The invention relates to the technical field of biomedicine, in particular to the application of leucanthin in the preparation of medicines for preventing and treating heart failure and pathological cardiac remodeling. The medicine uses leucanthin as an active ingredient, and can be mixed with pharmaceutically acceptable, inert, non-toxic excipients or carrier auxiliary materials to prepare a clinical medicine that is convenient for oral or intravenous application. Specifically, the application of leucetin in the preparation of anti-heart failure drugs, the application of leucetin in the preparation of anti-cardiac insufficiency drugs, the application of leucetin in the preparation of anti-pathological cardiac remodeling drugs, The role of leucanthin in the preparation of anti-cardiomyocyte hypertrophy drugs, the application of leucetin in the preparation of anti-cardiac interstitial fibrosis drugs, and the application of leucetin in the preparation of anti-cardiomyocyte death drugs.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Chinese medicinal preparation for treating early diabetic nephropathy and preparation method thereof
InactiveCN102100858BFunction increaseDelay the pathological processMetabolism disorderUrinary disorderTolerabilitySide effect
Owner:傅晓骏 +1
Nifurazide derivatives and their preparation methods and uses
ActiveCN113336729BPrevent proliferationInhibition of activationOrganic active ingredientsOrganic chemistryLung structureTherapeutic effect
The invention provides a nifurazide derivative and its preparation method and application, belonging to the field of chemical medicine. The structure of the nifurazide derivatives is shown in formula I. The nifurazide derivatives can effectively inhibit the proliferation of fibroblasts and the proliferation of human hepatic stellate cells, and most of the compounds have better inhibitory effects than nifurazide. The derivative can also reduce the proliferation of collagen fibers in the lung tissue of mice with pulmonary fibrosis, improve the interstitial fibrosis of mice, maintain the normal lung structure of mice, and even reverse the changes in lung structure of mice with pulmonary fibrosis. Humanized mice have good therapeutic effects and can be used to prepare candidate drugs for preventing and / or treating fibrosis. At the same time, the derivative has an excellent inhibitory effect on the proliferation of various tumor cells including breast cancer, colorectal adenocarcinoma, colon cancer and liver cancer, and can be used to prepare drug candidates for the prevention and / or treatment of various tumors. bright future.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Medicament composition for treating pulmonary interstitial fibrosis as well as preparation method and applications thereof
The invention discloses a medicament composition for treating pulmonary interstitial fibrosis as well as a preparation method and applications thereof, wherein the medicament composition for treating pulmonary interstitial fibrosis is prepared from the raw materials of winged euonymus, rhodiola rosea, polygala fallax hemsl, herba epimedii and honey-fried licorice root, and the percentage by weight of any component does not exceed 30% of the total weight. The medicament composition for treating pulmonary interstitial fibrosis as well as the preparation method and applications thereof provided by the invention breaks through the research and development convention, and are not limited to the traditional theory of traditional Chinese medicine; the pathogenesis of pulmonary interstitial fibrosis patient is intermingled with deficiency and excess; the root is deficiency of yang and congealing cold, and the symptom is stagnant phlegm and blood stasis; prescriptions are screened bravely and are combined; and the animal experiment and clinical experiment show that the medicament composition has the characteristic of obvious effect, and has favorable clinical application prospect.
Owner:江西中医学院附属医院
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com